<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Cardiol Heart Vasc</journal-id><journal-id journal-id-type="iso-abbrev">Int J Cardiol Heart Vasc</journal-id><journal-title-group><journal-title>International Journal of Cardiology. Heart &#x00026; Vasculature</journal-title></journal-title-group><issn pub-type="epub">2352-9067</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11681882</article-id><article-id pub-id-type="pii">S2352-9067(24)00242-2</article-id><article-id pub-id-type="doi">10.1016/j.ijcha.2024.101576</article-id><article-id pub-id-type="publisher-id">101576</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Prediction of stroke in patients with severe aortic stenosis by left atrial appendage filling defect patterns on early and late-phase computed tomography</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Lacaita</surname><given-names>Pietro G.</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>Bleckwenn</surname><given-names>Sven</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au015"><name><surname>Barbieri</surname><given-names>Fabian</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au020"><name><surname>Scharll</surname><given-names>Yannick</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au025"><name><surname>Deeg</surname><given-names>Johannes</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au030"><name><surname>Bonaros</surname><given-names>Nikolaos</given-names></name><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au035"><name><surname>Widmann</surname><given-names>Gerlig</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au040"><name><surname>Feuchtner</surname><given-names>Gudrun M.</given-names></name><email>gudrun.feuchtner@i-med.ac.at</email><xref rid="af005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><aff id="af005"><label>a</label>Department of Radiology, Innsbruck Medical University, Innsbruck, Austria</aff><aff id="af010"><label>b</label>Deutsches Herzzentrum der Charit&#x000e9;, Department of Cardiology, Angiology and Intensive Care Medicine, Berlin, Germany</aff><aff id="af015"><label>c</label>Department of Cardiac Surgery, Innsbruck Medical University, Innsbruck, Austria</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author at: Department of Radiology, Innsbruck Medical University, Anichstr. 35, A-6020 Innsbruck, Austria. <email>gudrun.feuchtner@i-med.ac.at</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>09</day><month>12</month><year>2024</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>09</day><month>12</month><year>2024</year></pub-date><volume>56</volume><elocation-id>101576</elocation-id><history><date date-type="received"><day>15</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>25</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>28</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 The Author(s)</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract abstract-type="author-highlights" id="ab005"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="o0005"><label>&#x02022;</label><p id="p0005">Persistent LAA-filling defects during the late phase of CTA and early-phase FDs with low Hounsfield Units are the strongest predictors of stroke in patients scheduled for TAVI, performing superior to conventional risk factors and the CHA2DS-Vasc-Score.</p></list-item><list-item id="o0010"><label>&#x02022;</label><p id="p0010">LAA filling defect patterns from CTA may improve stroke risk prediction in patients scheduled for TAVI over current clinical scores.</p></list-item><list-item id="o0015"><label>&#x02022;</label><p id="p0015">Future research is required how to integrate LAA filling parameters from CTA into conventional risk scores.</p></list-item></list></p></abstract><abstract id="ab010"><sec><title>Background</title><p>Stroke is a feared complication after TAVI. The objective was to assess whether left atrial appendage (LAA) filling-defect (FD) patterns from early and late-phase computed tomography (CT), predict stroke/TIA in patients with severe aortic stenosis.</p></sec><sec><title>Methods</title><p>124 patients with severe aortic stenosis (79.5y, 46.8% females) who underwent CT-Angiography for TAVI-planning were included (66.1% underwent TAVI, 18.6% surgical, 15.3% conservative treatment).CT-image-analysis included: CT-density (HU) from LAA tip-to-base and HU-gradients (I-III), the HU-ratio LAA/aorta, left-atrial-wall-thickness (LAWT) and the periatrial fat attenuation index (FAI).</p></sec><sec><title>Results</title><p>Stroke/TIA rate was 9.6&#x000a0;%. LAA-HU-gradient was slightly higher in non-stroke patients (p&#x000a0;=&#x000a0;0.087). Persisting FDs during the late-phase were associated with stroke (p&#x000a0;=&#x000a0;0.047) but not early-phase FDs. Early-phase FDs with HU&#x000a0;&#x0003c;&#x000a0;245 (n&#x000a0;=&#x000a0;15) were correlated with stroke (p&#x000a0;=&#x000a0;0.05). A LAA-HU-gradient&#x000a0;&#x0003e;&#x000a0;10HU had 91&#x000a0;% sensitivity and 68&#x000a0;% specificity for prediction of stroke. LAA-HU gradient I had a moderate accuracy (<italic>c&#x000a0;=&#x000a0;0.592;</italic> 95&#x000a0;%CI:0.472&#x02013;0.711; p&#x000a0;=&#x000a0;0.317) for discrimination of stroke during the early phase, which enhanced during the late phase (<italic>c&#x000a0;=&#x000a0;0.686</italic>;95&#x000a0;%CI:0.503&#x02013;0.868; p&#x000a0;=&#x000a0;0.046). Patients with stroke had a higher rate of FDs with HU-progression from early to late phase (&#x0003e;10HU)(p&#x000a0;=&#x000a0;0.013), while the ratios LAA/aorta, LAWT, and periatrial-FAI were not different. Among clinical parameters, only age predicted stroke but not CHA2DS2-VASc-score. In multivariate analysis, late-phase FDs (p&#x000a0;=&#x000a0;0.059)(OR 5.66: 95&#x000a0;%CI:0.936&#x02013;34.28) but not early-phase FD were associated with stroke, and none of the major conventional risk factors.</p></sec><sec><title>Conclusion</title><p>Persisting LAA-filling defects on CT during the late-phase, and early-phase FD with &#x0003c;245HU predict stroke, and a CT-density progression &#x0003e;10HU from early-to-late phase. LAA-FD may improve stroke risk stratification.</p></sec></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Computed tomography (CT)</kwd><kwd>CT-Angiography</kwd><kwd>TAVI</kwd><kwd>Left atrial appendage</kwd><kwd>Filling defects</kwd><kwd>Thrombus</kwd><kwd>Stroke</kwd></kwd-group></article-meta><def-list><title>Abbreviations</title><def-item><term id="k0045">TAVI</term><def><p>Transcatheter Aortic Valve Implantation</p></def></def-item><def-item><term id="k0055">LAA</term><def><p>Left Atrial Appendage</p></def></def-item><def-item><term id="k0065">FD</term><def><p>Filling Defect</p></def></def-item><def-item><term id="k0075">TEE</term><def><p>transesophageal echocardiography</p></def></def-item><def-item><term id="k0085">CTA</term><def><p>Computed Tomography Angiography</p></def></def-item><def-item><term id="k0095">HU</term><def><p>Hounsfield Units</p></def></def-item><def-item><term id="k0105">LAWT</term><def><p>Left Atrial Wall Thickness</p></def></def-item><def-item><term id="k0115">FAI</term><def><p>Fat Attenuation Index</p></def></def-item><def-item><term id="k0125">ECG</term><def><p>Electrocardiogram</p></def></def-item><def-item><term id="k0135">SAVR</term><def><p>Surgical Aortic Valve Replacement</p></def></def-item><def-item><term id="k0145">MRI</term><def><p>Magnetic Resonance Imaging</p></def></def-item><def-item><term id="k0155">GFR</term><def><p>Glomerular Filtration Rate</p></def></def-item><def-item><term id="k0165">CVRF</term><def><p>Cardiovascular risk factors</p></def></def-item><def-item><term id="k0175">ESC</term><def><p>European Society of Cardiology</p></def></def-item><def-item><term id="k0185">BP</term><def><p>Blood Pressure</p></def></def-item><def-item><term id="k0195">MI</term><def><p>Myocardial Infarction</p></def></def-item><def-item><term id="k0205">TIA</term><def><p>Transient Ischemic Attack</p></def></def-item><def-item><term id="k0215">ROC</term><def><p>Receiver Operating Characteristic</p></def></def-item><def-item><term id="k0225">OR</term><def><p>Odds Ratio</p></def></def-item><def-item><term id="k0235">SD</term><def><p>Standard Deviation</p></def></def-item><def-item><term id="k0245">IQR</term><def><p>Interquartile Range</p></def></def-item><def-item><term id="k0255">BMI</term><def><p>Body Mass Index</p></def></def-item><def-item><term id="k0265">PCI</term><def><p>Percutaneous Coronary Intervention</p></def></def-item><def-item><term id="k0275">CABG</term><def><p>Coronary Artery Bypass Grafting</p></def></def-item><def-item><term id="k0285">NOAC</term><def><p>Novel Oral Anticoagulant</p></def></def-item><def-item><term id="k0295">DAPT</term><def><p>Dual Antiplatelet Therapy</p></def></def-item></def-list></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0020">Transcatheter aortic valve implantation (TAVI) has emerged as a state-of-the-art treatment for severe aortic stenosis, but stroke remains one of its most feared and debilitating complications, occurring in 1.7&#x000a0;% to 4.8&#x000a0;% of cases <xref rid="b0005" ref-type="bibr">[1]</xref>, <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>. Despite recent reductions in the 30-day mortality rate <xref rid="b0025" ref-type="bibr">[5]</xref>, stroke rates after TAVI remain higher compared to surgical aortic valve replacement (SAVR) <xref rid="b0030" ref-type="bibr">[6]</xref>. The incidence of silent cerebral perfusion deficits detected by MRI after TAVI is even higher <xref rid="b0035" ref-type="bibr">[7]</xref>, emphasizing the importance of stroke prevention strategies. Despite the use of embolic protection devices has decreased the risk of stroke, the reduction was minor <xref rid="b0040" ref-type="bibr">[8]</xref>. While several strategies to prevent stroke after TAVI have been reported <xref rid="b0045" ref-type="bibr">[9]</xref>, identifying high-risk patients remains a challenge. In 2019, Thourani et al. described a risk score based on clinical risk factors, which has a moderate accuracy with c&#x000a0;=&#x000a0;0.62 <xref rid="b0050" ref-type="bibr">[10]</xref>. While the pathogenesis of stroke immediately after TAVI is supposed to be rather embolic than atherothrombotic or hemorrhagic <xref rid="b0005" ref-type="bibr">[1]</xref>, the most common source is not clear. Stroke is also a common event in all patients with severe aortic stenosis, whether they undergo surgical treatment or not, due their high age, high cardiovascular risk profile, high frailty and high burden of systemic atherosclerosis.</p><p id="p0025">Left atrial thrombi are well-established risk factors for stroke <xref rid="b0055" ref-type="bibr">[11]</xref> and mortality <xref rid="b0060" ref-type="bibr">[12]</xref>, but the role of pre-thrombotic stages like sludge with pro-coagulopathic particles accumulating in the left atrial appendage (LAA) is less clear but gaining attention for the prediction of stroke. Spontaneous echo contrast (SEC) <xref rid="b0065" ref-type="bibr">[13]</xref> on transthoracic or transesophageal echocardiography (TEE) represents a pre-thrombotic stage, with pro-coagulopathic particles accumulating in the LAA <xref rid="b0065" ref-type="bibr">[13]</xref>. The use of transthoracic and TEE to screen for cardiac emboli has been established in clinical practice <xref rid="b0070" ref-type="bibr">[14]</xref>.</p><p id="p0030">Coronary CT- Angiography (CTA) is the modality of choice for planning of TAVI and other surgical procedures. However, distinguishing thrombi from sludge and from mere artificial filling detects (FD) due to stasis is a major challenge for CTA. During the early phase, a LAA FD with low CT density can represent both a thrombus or an artificial FD due to blood flow stasis <xref rid="b0075" ref-type="bibr">[15]</xref>, and the false positive rate of CTA is high, while late-phase CT scans reduce the rate of false-positive findings on CTA. If a FD does not resolve during the late phase, a thrombus is very likely. <xref rid="b0080" ref-type="bibr">[16]</xref>. However, late-phase CT scans generate additional radiation and contrast volume exposure; therefore, they are not performed routinely during a CTA in patients scheduled for surgical intervention <xref rid="b0085" ref-type="bibr">[17]</xref>.</p><p id="p0035">Therefore, objective of our study was to evaluate which quantitative LAA FD patterns including novel parameters (absolute Hounsfield Units (HU), gradient HU, ratio HU LAA/Aorta) during early and late phase, and other LAA morphological parameters (periatrial fat attenuation index (FAI) and left atrial wall thickness (LAWT)) from CT predict stroke in patients with severe aortic stenosis scheduled for transcatheter or surgical aortic valve intervention.</p></sec><sec id="s0010"><label>2</label><title>Material and methods</title><sec id="s0015"><label>2.1</label><title>Study design and population</title><p id="p0040">Patients with severe aortic stenosis who underwent electrocardiogram (ECG)-gated combined coronary and aortic CTA during 2018 and 2019 for planning of TAVI due to clinical indications were included in this retrospective single center study. Patients were scheduled for CTA after the interdisciplinary heart team, consisting of cardiac surgeons, cardiologists, radiologists, and anesthesiologists, has discussed the individual risk and appropriateness of the candidates for TAVI. Because only a limited number of procedures were permitted to be carried out per year due to financial restrictions, only very high-risk patients could be selected. Institutional review board (IRB) approval was obtained. Written informed consent was waived by IRB.</p></sec><sec id="s0020"><label>2.2</label><title>Inclusion criteria were</title><p id="p0045">Patients with severe symptomatic aortic stenosis and a high cardiac operative risk (including those with 20&#x000a0;% or more), meeting the criteria for surgical intervention <xref rid="b0090" ref-type="bibr">[18]</xref>, were selected as potential candidates for TAVI by our interdisciplinary heart team and scheduled for CTA. Diagnosis of severe aortic stenosis was made by transthoracic echocardiography according to standardized criteria <xref rid="b0090" ref-type="bibr">[18]</xref>. <bold>Exclusion criteria</bold> for CTA were: severe renal dysfunction (glomerular filtration rate (GFR)&#x000a0;&#x0003c;&#x000a0;30&#x000a0;ml/min), untreated hyperthyreosis, prior iodine contrast allergy without adequate premedication and pregnancy. For TAVI, exclusion criteria were active endocarditis, myocardial infarction within 14&#x000a0;days, cardiogenic shock, and a life expectancy of less than 1&#x000a0;year.</p><p id="p0050">Major <bold>traditional cardiovascular risk factors (CVRF)</bold> were collected and defined according to standardized European Society of Cardiology (ESC) criteria arterial hypertension (systolic blood pressure (BP)&#x000a0;&#x0003e;&#x000a0;140&#x000a0;mmHg or diastolic BP&#x000a0;&#x0003e;&#x000a0;90&#x000a0;mmHg), dyslipidemia, positive family history (myocardial infarction (MI) or sudden cardiac death in an immediate male relative&#x000a0;&#x0003c;&#x000a0;55&#x000a0;years or female&#x000a0;&#x0003c;&#x000a0;65&#x000a0;years), smoker (active: current or quit less than 6&#x000a0;months before coronary CTA examination and former), and diabetes <xref rid="b0095" ref-type="bibr">[19]</xref>, <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>. Further clinical parameters, all co-morbidities (including coronary artery disease, myocardial infarct, prior stroke), stroke event details (TIA vs stroke), CHA2DS2-VASc score, and medications were collected. All data were retrieved from our internal hospital documentation system, and recorded by board-certified physicians.</p></sec><sec id="s0025"><label>2.3</label><title>Computed tomography (CT)</title><p id="p0055">A 128-slice dual-source CT (<italic>Definition FLASH or DRIVE, Siemens Healthineers, Erlangen, Germany</italic>) scanner with a detector collimation of 2&#x000a0;&#x000d7;&#x000a0;64&#x000a0;&#x000d7;&#x000a0;0.6&#x000a0;mm and a rotation time of 0.28&#x000a0;s was used. Scans were triggered into the arterial phase using bolus tracking (threshold of 100 HU, ascending aorta) and by injecting an intravenous iodine contrast agent (<italic>Iopromide, Ultravist 370</italic>&#x02122;, Bayer Healthcare, Berlin, Germany<italic>)</italic>. A 2-step CT scan protocol was deployed: First, a CT-Angiography scan during arterial phase (&#x0201c;early phase&#x0201d;) was performed: A retrospective ECG-gated helical CTA of the heart with image acquisition during both systolic and diastolic phases was acquired with a bolus of 60&#x02013;110&#x000a0;ml iodine contrast agent. The amount of contrast agent was adjusted to a patien&#x00074;&#x00301;s individual body weight using a standardized regimen. The CT scan was triggered into the arterial phase (ascending aorta, threshold 100 HU) by using automated bolus tracking. Second, a CT-Angiography scan during late phase was performed after a delay of over 5&#x000a0;min. Prospective ECG-triggered CTA covering the entire thoracic and abdominal/pelvic scan for the evaluation of vascular access routes was conducted with high-pitch mode (pitch, 3.2), triggered into diastolic phase (60&#x000a0;% of RR-interval) and into arterial phase, as outlined above.</p></sec><sec id="s0030"><label>2.4</label><title>CT image postprocessing</title><p id="p0060">Axial thin slice images were reconstructed with a 1.0&#x000a0;mm slice width (increment, 0.7) and transferred to clinically approved radiology software (DeepUnity Diagnostic 1.2.0.1, Dedalus, DH Healthcare, Bonn, Germany). The following measurements were taken:</p></sec><sec id="s0035"><label>2.5</label><title>CT image analysis</title><p id="p0065">First<bold>,</bold> the CT density of the LAA (HU) was measured by locating the left atrial appendage (LAA) and placing three round-shaped region of interest (ROI) from the tip to the bottom (apex/mid/basal) without filling defect (<xref rid="f0005" ref-type="fig">Fig. 1</xref>a &#x02013; normal LAA filled with contrast agent) and a filling defect (<xref rid="f0010" ref-type="fig">Fig. 2</xref>a), and by placing one large ROI centrally in the left atrial appendage (normal, filled with contrast agent) without filling defect (<xref rid="f0005" ref-type="fig">Fig. 1</xref>b) and similarly, into a LAA filling defect (<xref rid="f0010" ref-type="fig">Fig. 2</xref>b). A filling defect was defined as a hypoattenuating region within the LAA, not filled with contrast agent. The diameter of the filling defect (FD) was measured with a virtual caliper. Second, the ratio of the CT density of the LAA to the ascending aorta (HU) was calculated after placing a large ROI into the ascending aorta. Third, left atrial wall thickness (LAWT) was measured at three different sites using the virtual ruler (<xref rid="f0015" ref-type="fig">Fig. 3</xref>a) along the anterior left atrial ridge. The CT slice was located approximately at the bifurcation of the left coronary artery (LCA) into the circumflex artery (CX) and the left anterior descending (LAD). Forth, the periatrial fat attenuation index (FAI) was measured by placing three different ROIs arranged in a row adjacent to the tip of the LAA (<xref rid="f0015" ref-type="fig">Fig. 3</xref>b). The same measurements were repeated in the corresponding late-phase protocol (if available) by one experienced observer. Three different LAA HU gradients were calculated as follows: gradient I (between ROI 1 (tip) and ROI 3 (bottom)), gradient II (between ROI 1 (tip) and ROI 2 (mid)), and gradient III (between ROI 2 (mid) and ROI 3 (bottom)). A &#x0201c;persisting FD&#x0201d; was defined as a lack of LAA filling during late phase. Further, the LAA HU progression from early to late phase was calculated as a novel quantitative LAA parameter for prediction of stroke.<fig id="f0005"><label>Fig. 1</label><caption><p>A LAA CT density (HU) quantification: 3 regions of interest (ROI) were placed from LAA tip to the bottom and the gradient was calculated. A normal LAA, entirely filled with contrast agent, is shown. B: Mean LAA HU density of a normal LAA: A large ROI was placed into the LAA.</p></caption><graphic xlink:href="gr1a" id="lk00005"/><graphic xlink:href="gr1b" id="lk00095"/></fig><fig id="f0010"><label>Fig. 2</label><caption><p>A: LAA filling defect (FD): Measurement of the HU gradient from the tip to the bottom: 3 ROI were drawn from LAA tip to the bottom. HU 1 (top), HU 2 (mid section), HU 3 (bottom) B: Mean HU of the LAA FD was quantified by placing one large ROI.</p></caption><graphic xlink:href="gr2a" id="lk00010"/><graphic xlink:href="gr2b" id="lk00910"/></fig><fig id="f0015"><label>Fig. 3</label><caption><p>A: Left atrial wall thickness (LAWT) was measured at 3 different sites along the left atrial ridge. B: The periatrial fat attenuation index (FAI) was measured adjacent of the tip of the LAA.</p></caption><graphic xlink:href="gr3a" id="lk00015"/><graphic xlink:href="gr3b" id="lk00715"/></fig></p></sec><sec id="s0040"><label>2.6</label><title>TAVI procedure, surgical technique</title><p id="p0070">TAVI was performed in hybrid operating rooms equipped with an invasive angiography suite by an interdisciplinary heart team consisting of both cardiac surgeons and interventional cardiologists. A transfemoral or transaxillary access route was chosen. Prosthesis sizing was based on CTA annulus dimensions. TAVI was conducted with transesophageal and intracardiac echocardiography under fluoroscopic guidance, and with general anesthesia.</p></sec><sec id="s0045"><label>2.7</label><title>Outcomes</title><p id="p0075">Cerebrovascular events, were defined as either a stroke (diagnosed with clinical and imaging (CT/MR) criteria) in accordance with the recommendation by the Academic Research Consortium Initiative <xref rid="b0110" ref-type="bibr">[22]</xref>, or transient ischemic attack (TIA)- defined as neurological deficit lasting &#x02265;24&#x000a0;h or lasting &#x0003c;24&#x000a0;h with a brain imaging study (MRI and/or CT) providing evidence.</p></sec><sec id="s0050"><label>2.8</label><title>Statistical analysis</title><p id="p0080">Statistical analysis was performed using SPSS&#x02122; software (V25.0, SPSS Inc., Chicago, USA). Quantitative variables are expressed as means&#x000a0;&#x000b1;&#x000a0;standard deviation (SD) or as median (IQR), according to their distribution, and categorical variables as absolute values and percentages.&#x000a0;Normal distribution of data was tested with Kolomogorov-Smirnow test and histogramm. Chi-square test was applied to test for differences in categorical data. Independent <italic>t</italic>-test was applied to test for differences in parametric and normally distributed data (such as age, body mass index (BMI), and CT LAA imaging data) among stroke and non-stroke patients.</p><p id="p0085">Receiver Operating Curves (ROC) were generated to define the diagnostic accuracy (c-value) of all quantitative CT imaging LAA parameters listed in the methods for prediction of stroke. Univariate and multivariate binary regression analysis were generated for prediction of stroke by CT imaging parameters, the major cardiovascular risk factors and the CHA2DS-VASc-Score.</p></sec></sec><sec id="s0055"><label>3</label><title>Results</title><p id="p0090">This retrospective study included 124 patients, 46.8&#x000a0;% of whom were female (<xref rid="t0005" ref-type="table">Table 1</xref>). Out of 124 patients with severe aortic stenosis, 66.1&#x000a0;% underwent TAVI, 18.6&#x000a0;% underwent surgical treatment, and 15.3&#x000a0;% received conservative treatment (<xref rid="t0010" ref-type="table">Table 2</xref>). The average age was 79.4&#x000a0;&#x000b1;&#x000a0;7.1&#x000a0;years, with a range of 52 to 89&#x000a0;years. <xref rid="t0005" ref-type="table">Table 1</xref> shows the study cohort profile, including differences between stroke patients and those who did not have a stroke.<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>Study cohort: patient profile (n&#x000a0;=&#x000a0;124).</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th><bold>n&#x000a0;=&#x000a0;124</bold></th><th><bold>Stroke (n&#x000a0;=&#x000a0;12)</bold></th><th><bold>No Stroke (n&#x000a0;=&#x000a0;112)</bold></th><th><bold>p-value</bold></th></tr></thead><tbody><tr><td><bold>Age (years)</bold></td><td>79.4&#x000a0;&#x000b1;&#x000a0;7.1</td><td>83.3&#x000a0;&#x000b1;&#x000a0;5.5</td><td>79.0&#x000a0;&#x000b1;&#x000a0;7.2</td><td>0.023*</td></tr><tr><td><bold>BMI (kg/m<sup>2</sup>)</bold></td><td>26.2&#x000a0;&#x000b1;&#x000a0;4.9</td><td>24.3&#x000a0;&#x000b1;&#x000a0;5.1</td><td>26.4&#x000a0;&#x000b1;&#x000a0;4.8</td><td>0.196</td></tr><tr><td><bold>Female (%)</bold></td><td>58 (46.8)</td><td>6/12 (50)</td><td>52/112 (46.4)</td><td>0.81</td></tr><tr><td><bold>Arterial Hypertension (%)</bold></td><td>88/124 (71.0)</td><td>8/12 (66.7)</td><td>80/112 (71.4)</td><td>0.73</td></tr><tr><td><bold>Nicotine Abuse (%)</bold></td><td>31/124 (25)</td><td>1/12 (8.3)</td><td>30/112 (26.8)</td><td>0.16</td></tr><tr><td><bold>Family History (%)</bold></td><td>40/124 (32.3)</td><td>5/12 (41.7)</td><td>35/112 (31.3)</td><td>0.46</td></tr><tr><td><bold>Dyslipidemia (%)</bold></td><td>88/124 (71.0)</td><td>7/12 (58.3)</td><td>81/112 (72.3)</td><td>0.31</td></tr><tr><td><bold>Diabetes (%)</bold></td><td>28/124 (22.6)</td><td>1/12 (8.3)</td><td>27/112 (24.1)</td><td>0.21</td></tr><tr><td><bold>Obesity (%)</bold></td><td>22/124 (17.7)</td><td>1/12 (8.3)</td><td>21/112 (18.8)</td><td>0.37</td></tr><tr><td><bold>Pre-obesity (%)</bold></td><td>46/124 (37.1)</td><td>7/12 (58.3)</td><td>39/112 (34.8)</td><td>0.11</td></tr><tr><td><bold>Typical chest pain(%)</bold></td><td>42/124 (33.9)</td><td>3/12 (25)</td><td>39/112 (34.8)</td><td>0.49</td></tr><tr><td><bold>History of Myocardial Infarction (%)</bold></td><td>19/124 (15.3)</td><td>3/12 (25)</td><td>16/112 (14.3)</td><td>0.33</td></tr><tr><td><bold>History of Stent/PCI (%)</bold></td><td>34/124 (27.4)</td><td>6/12 (50)</td><td>28/112 (25)</td><td>0,066</td></tr><tr><td><bold>History of CABG (%)</bold></td><td>13/124 (10.5)</td><td>1/12 (8.3)</td><td>13/112 (11.6)</td><td>0.021*</td></tr><tr><td><bold>History of Stent &#x00026; CABG (%)</bold></td><td>5/124 (4.0)</td><td>0/12 (0)</td><td>5/112 (4.46)</td><td>0,455</td></tr><tr><td><bold>Atrial Fibrillation (%)</bold></td><td>58/124 (46.8)</td><td>7/12 (58.3)</td><td>51/112 (45.5)</td><td>0.27</td></tr><tr><td><bold>Aspirin (%)</bold></td><td>77/124 (62.1)</td><td>9/12 (75)</td><td>68/112 (60.7)</td><td>0.33</td></tr><tr><td><bold>NOAC (%)</bold></td><td>30/124 (24.2)</td><td>2/12 (16.7)</td><td>28/112 (25)</td><td>0.52</td></tr><tr><td><bold>DAPT (%)</bold></td><td>19/124 (15.3)</td><td>1/12 (8.3)</td><td>18/112 (16.1)</td><td>0.48</td></tr><tr><td><bold>Vitamin K Antagonists (%)</bold></td><td>9/124 (7.3)</td><td>1/12 (8.3)</td><td>8/112 (7.1)</td><td>0.88</td></tr><tr><td><bold>Pacemaker (%)</bold></td><td>16/124 (12.9)</td><td>1/12 (8.3)</td><td>15/112 (13.4)</td><td>0.62</td></tr></tbody></table><table-wrap-foot><fn><p>Parametric variables are expressed as means&#x000a0;&#x000b1;&#x000a0;standard deviation (SD), categorical variables as absolute values (N) and percentages (%). BMI = body mass index. CABG: Coronary artery bypass grafting. NOAC&#x000a0;=&#x000a0;novel oral anticoagulant DAPT&#x000a0;=&#x000a0;Dual antiplatelet therapy.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>Procedure related results.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th><bold>n&#x000a0;=&#x000a0;124</bold></th></tr></thead><tbody><tr><td><bold>Age (years)</bold></td><td>79.4&#x000a0;&#x000b1;&#x000a0;7.1</td></tr><tr><td><bold>CHA2DS2-VASc-Score</bold></td><td>4.05&#x000a0;&#x000b1;&#x000a0;1.7</td></tr><tr><td><bold>TAVI (%)</bold></td><td>82 (66.1)</td></tr><tr><td><bold>SAVR (%)</bold></td><td>23 (18.5)</td></tr><tr><td><bold>Conservative (%)</bold></td><td>19 (15.3)</td></tr><tr><td><bold>Stroke Rate (overall) (%)</bold></td><td>12/124 (9.6)</td></tr><tr><td><bold>Stroke Rate (TAVI) (%)</bold></td><td>12/82 (14.6)</td></tr><tr><td><bold>Stroke Rate (SAVR) (%)</bold></td><td>0/23 (0)</td></tr><tr><td><bold>Pre-TAVI Events (%)</bold></td><td>17/124 (13.7)</td></tr><tr><td><bold>CTA to OP (days)</bold></td><td>62.7&#x000a0;&#x000b1;&#x000a0;82.8</td></tr><tr><td><bold>CT (Early- % Late phase) (%)</bold></td><td>77/124 (62.1)</td></tr><tr><td><bold>Filling Defects (Early phase) (%)</bold></td><td>n&#x000a0;=&#x000a0;25 (20.2)</td></tr><tr><td><bold>Filling Defects (Late phase) (%)</bold></td><td>n&#x000a0;=&#x000a0;10 (8.1)</td></tr><tr><td><bold>Filling Defects (both phases) (%)</bold></td><td>n&#x000a0;=&#x000a0;10 (8.1)</td></tr><tr><td><bold>Filling defect disappeared in 2nd phase (%)</bold></td><td>11/25 (44)</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: TAVI: Transcatheter aortic valve replacement, SAVR: Surgical Aortic Valve Replacement.</p></fn></table-wrap-foot></table-wrap></p><p id="p0095">The mean CHA2DS-VASc-Score was 4.05&#x000a0;&#x000b1;&#x000a0;1.7 (range, 0&#x02013;9). There was no statistically significant difference in cardiovascular risk factors between stroke patients and those who did not have a stroke. Only age (p&#x000a0;=&#x000a0;0.023) was higher in stroke patients, while BMI was not different. EuroScore II was 15.23 +/- 3.1 SD.</p><p id="p0100">Additionally, 50&#x000a0;% of the stroke group had a previous intervention with coronary stents, which was not different from the event-free group (p&#x000a0;=&#x000a0;0.066). The event-free group had more patients who underwent coronary artery bypass grafting (CABG) (p&#x000a0;=&#x000a0;0.021). CTA revealed no difference in the proportion of those with obstructive coronary artery disease (&#x0003e;50&#x000a0;% coronary stenosis) between stroke and non-stroke patients (77.8&#x000a0;% vs 72.9&#x000a0;%, p&#x000a0;=&#x000a0;0.753). The prevalence of atrial fibrillation was similar between the groups (58.3&#x000a0;% vs. 45.5&#x000a0;%, p&#x000a0;=&#x000a0;0.27). Ten of the 16 patients with pacemakers were placed during or shortly after the intervention. There were no significant differences between the groups in terms of continuous anticoagulant drug use.</p><p id="p0105">Clinical outcomes: <xref rid="t0010" ref-type="table">Table 2</xref> shows outcomes, treatment, and CT results of the entire cohort: The time interval between CT and surgical intervention was on average 62.8&#x000a0;&#x000b1;&#x000a0;82.84&#x000a0;days (range, 3 to 514&#x000a0;days). The cerebrovascular event rate during the observed period was n&#x000a0;=&#x000a0;12 (9.6&#x000a0;%). Nine stroke events (75&#x000a0;%) and n&#x000a0;=&#x000a0;3 TIA (25&#x000a0;%) were recorded. Of nine strokes, n&#x000a0;=&#x000a0;1 died related to a large medial cerebral artery territorial infarct, followed by coma and death. There were n&#x000a0;=&#x000a0;3 medial cerebral artery (MCA) partial or complete territorial infarcts (of which n&#x000a0;=&#x000a0;1 also had additional embolic lesions), 1 patient with both medial cerebral artery infarct and posterior infarct right, n&#x000a0;=&#x000a0;1 infarct with intracerebral hemorrhage (ICH), n&#x000a0;=&#x000a0;2 posterior/occipital infarcts, n&#x000a0;=&#x000a0;1 small cortical frontoparietal, and n&#x000a0;=&#x000a0;1 subcortical embolic stroke events. All TIA events were cardioembolic and verified by MRI. Symptoms of patients with TIA were: n&#x000a0;=&#x000a0;1 hemiparesis and aphasia, and n&#x000a0;=&#x000a0;2 typical MCA TIA related symptoms. The 12&#x000a0;Stroke events occurred in the TAVI group only (100&#x000a0;%), while no strokes (0&#x000a0;%) were recorded in the SAVR or conservatively treated groups. Time from CT to the stroke event was mean 206.5&#x000a0;days&#x000a0;&#x000b1;&#x000a0;275 SD (range, 0&#x02013;792&#x000a0;days). There were only 3 events (25&#x000a0;%) within 30&#x000a0;days (short term) and 9 (75&#x000a0;%) events occurred during long- term follow up (&#x0003e;=30&#x000a0;days).</p><p id="p0110">Left atrial appendage filling defects (LAA) patterns by CTA: Early-phase CTA protocols were available for all 124 patients, and 62.1&#x000a0;% had a corresponding late-phase protocols. Among the 124 early-phase CTAs, a filling defect (FD) was observed in 25 cases (20.2&#x000a0;%). Of these, 10 FDs (40&#x000a0;%) persisted in the late phase, while 11 (44&#x000a0;%) resolved (artificial filling defects). In 4 cases, an early-phase FD could not be followed up due to the lack of a late-phase CT (additional contrast could not be administered due to renal dysfunction).&#x000a0;<xref rid="t0015" ref-type="table">Table 3a</xref>&#x000a0;shows the quantitative CT parameters of LAA FDs during early and late phases. Persisting FD during late phase had a significantly higher CT density of 233.19 HU compared to early arterial FDs (p&#x000a0;=&#x000a0;0.004). Persisting FDs during late-phase were associated with stroke (p&#x000a0;=&#x000a0;0.047) on univariate binary regression but not early-phase FD (<xref rid="t0020" ref-type="table">Table 3b</xref>).&#x000a0;Early-phase FD with less than 245 HU (n&#x000a0;=&#x000a0;15) were correlated with stroke (p&#x000a0;=&#x000a0;0.05), but not those with higher HU above 245 HU.<table-wrap position="float" id="t0015"><label>Table 3a</label><caption><p>Quantitative CT-Parameters of LAA filling defects (FD): absolute values.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th><bold>Early Phase (n&#x000a0;=&#x000a0;25)</bold></th><th><bold>Late Phase (n&#x000a0;=&#x000a0;10)</bold></th></tr></thead><tbody><tr><td><bold>Filling Defects (%)</bold></td><td>25/124 (20.2)</td><td>10/77 (13)</td></tr><tr><td><bold>Size of Filling Defects (mm)</bold></td><td>19.8&#x000a0;&#x000b1;&#x000a0;6.5</td><td>20.2&#x000a0;&#x000b1;&#x000a0;7.3</td></tr><tr><td><bold>Ascending aorta (HU)</bold></td><td>433.6&#x000a0;&#x000b1;&#x000a0;82.8</td><td>386.7&#x000a0;&#x000b1;&#x000a0;86.8</td></tr><tr><td><bold>LAA 1 (HU)</bold></td><td>124.8&#x000a0;&#x000b1;&#x000a0;97.6</td><td>219.0&#x000a0;&#x000b1;&#x000a0;119.8</td></tr><tr><td><bold>LAA 2 (HU)</bold></td><td>137.1&#x000a0;&#x000b1;&#x000a0;99.7</td><td>230.9&#x000a0;&#x000b1;&#x000a0;113.1</td></tr><tr><td><bold>LAA 3 (HU)</bold></td><td>156.4&#x000a0;&#x000b1;&#x000a0;108.4</td><td>249.7&#x000a0;&#x000b1;&#x000a0;112.7</td></tr><tr><td><bold>Sum of HU 1</bold>&#x02013;<bold>3 (mean)</bold></td><td>139.4&#x000a0;&#x000b1;&#x000a0;98.7</td><td>233.2&#x000a0;&#x000b1;&#x000a0;113.3</td></tr><tr><td><bold>LAA Mean (HU)*</bold></td><td>136.2&#x000a0;&#x000b1;&#x000a0;91.2</td><td>222.7&#x000a0;&#x000b1;&#x000a0;112.2</td></tr></tbody></table><table-wrap-foot><fn id="sp0075"><p>*one large ROI.</p></fn><fn id="sp0080"><p>Abbreviations: HU = Hounsfield Units. LAA = left atrial appendage.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0020"><label>Table 3b</label><caption><p>Univariate binary logistic regression testing for prediction of stroke: Among FD, only persisting FD during late phase showed a significant association with stroke, but not early phase.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th><bold>OR</bold></th><th><bold>95&#x000a0;% CI</bold></th><th><bold>p-value</bold></th></tr></thead><tbody><tr><td><bold>Persisting FD during late phase</bold></td><td align="char">5.229</td><td>1.023 &#x02013; 26.716</td><td align="char">0.047*</td></tr><tr><td><bold>FD during early phase</bold></td><td align="char">2.167</td><td>0.596&#x02013;&#x02013;7.876</td><td align="char">0.240</td></tr><tr><td><bold>FD disappeared during late phase</bold></td><td align="char">4.286</td><td>0.094&#x02013;9.249</td><td align="char">0.246</td></tr><tr><td><bold>CHA2DS2-VASc-Score</bold></td><td align="char">1.353</td><td>0.939&#x02013;1.951</td><td align="char">0.105</td></tr></tbody></table></table-wrap></p><p id="p0115"><xref rid="t0025" ref-type="table">Table 4</xref> shows quantitative CT-density (HU) values of the LAA and HU gradients during early and late phase. LAA HU-gradient I was slightly higher in non-stroke patients, although not statistically significant. (50.6 HU vs 34.9 HU; p&#x000a0;=&#x000a0;0.087), while all other gradients I-III were not different. On ROC analysis, among the different HU Gradients I, II, and III during early phase, HU Gradient I had the highest accuracy (c&#x000a0;=&#x000a0;0.592; 95&#x000a0;% CI: 0.472&#x02013;0.711; p&#x000a0;=&#x000a0;0.317) for prediction of stroke (<xref rid="s0090" ref-type="sec">Supplement 1</xref>), as compared to gradients II and III (c&#x000a0;=&#x000a0;0.358; 95&#x000a0;%CI: 0.192&#x02013;0.523; p&#x000a0;=&#x000a0;0.120 and c&#x000a0;=&#x000a0;0.544; 95&#x000a0;%CI: 0.372&#x02013;0.716, p&#x000a0;=&#x000a0;0.632). Similarly, during late phase, Gradient II and III had a lower accuracy (c&#x000a0;=&#x000a0;0.543; 95&#x000a0;% CI: 0.392&#x02013;0.695, p&#x000a0;=&#x000a0;0.575, and c&#x000a0;=&#x000a0;0.583; 95&#x000a0;% CI: 0.316&#x02013;0.851, p&#x000a0;=&#x000a0;0.542) compared to gradient I (c&#x000a0;=&#x000a0;0.686; 95&#x000a0;% CI: 0.503&#x02013;0.868; p&#x000a0;=&#x000a0;0.046), which was the only significantly predictor of stroke (<xref rid="s0090" ref-type="sec">Supplement 1</xref>). A LAA gradient of&#x000a0;&#x0003e;&#x000a0;10HU had the highest (91&#x000a0;%) sensitivity and 68&#x000a0;% specificity for prediction of stroke. Finally, patients with stroke had a higher rate of FDs with HU progression (&#x0003e;10HU) from early to late phase (25&#x000a0;% vs 5.4&#x000a0;%; p&#x000a0;=&#x000a0;0.013).<table-wrap position="float" id="t0025"><label>Table 4</label><caption><p>LAA HU-Gradients during early and late CT phase in all patients, including those with normally filled LAA: Between patients with and without stroke, no significant differences were found.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="5"><bold>Early phase</bold></th></tr><tr><th/><th><bold>Stroke (n&#x000a0;=&#x000a0;12)</bold></th><th><bold>No Stroke (n&#x000a0;=&#x000a0;112)</bold></th><th><bold>Total (n&#x000a0;=&#x000a0;124)</bold></th><th><bold>2-sided p-value</bold></th></tr></thead><tbody><tr><td><bold>HU 1 (Top)</bold></td><td>342.8&#x000a0;&#x000b1;&#x000a0;200.6</td><td>361.0&#x000a0;&#x000b1;&#x000a0;162.4</td><td>359.3&#x000a0;&#x000b1;&#x000a0;165.2</td><td align="char">0.919<break/></td></tr><tr><td><bold>HU 2 (Mid)</bold></td><td>349.2&#x000a0;&#x000b1;&#x000a0;191.5</td><td>362.6&#x000a0;&#x000b1;&#x000a0;153.2</td><td>361.4&#x000a0;&#x000b1;&#x000a0;156.1</td><td align="char">0.825</td></tr><tr><td><bold>HU 3 (Bottom)</bold></td><td>349.8&#x000a0;&#x000b1;&#x000a0;189.9</td><td>372.5&#x000a0;&#x000b1;&#x000a0;151.8</td><td>370.5&#x000a0;&#x000b1;&#x000a0;154.8</td><td align="char">0.972</td></tr><tr><td><bold>HU (Mean)</bold></td><td>347.3&#x000a0;&#x000b1;&#x000a0;193.3</td><td>364.5&#x000a0;&#x000b1;&#x000a0;154.3</td><td>362.9&#x000a0;&#x000b1;&#x000a0;157.3</td><td align="char">0.926</td></tr><tr><td><bold>Gradient I</bold><break/><bold>(HU 3</bold>&#x02013;<bold>1)</bold></td><td>29.5&#x000a0;&#x000b1;&#x000a0;13.3</td><td>32.1&#x000a0;&#x000b1;&#x000a0;35.1</td><td>31.8&#x000a0;&#x000b1;&#x000a0;33.7</td><td align="char">0.316</td></tr><tr><td><bold>Gradient II</bold><break/><bold>(HU 1</bold>&#x02013;<bold>2)</bold></td><td>16.6&#x000a0;&#x000b1;&#x000a0;15.0</td><td>28.3&#x000a0;&#x000b1;&#x000a0;29.8</td><td>27.2&#x000a0;&#x000b1;&#x000a0;28.9</td><td align="char">0.120</td></tr><tr><td><bold>Gradient III (HU 2</bold>&#x02013;<bold>3)</bold></td><td>23.3&#x000a0;&#x000b1;&#x000a0;24.5</td><td>25.4&#x000a0;&#x000b1;&#x000a0;24.5</td><td>24.1&#x000a0;&#x000b1;&#x000a0;29.7</td><td align="char">0.632</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th colspan="5"><bold>Late phase</bold></th></tr><tr><th><bold>HU 1 (Top)</bold></th><th>273.0 &#x000b1; 152.4</th><th>348.3 &#x000b1; 151.0</th><th>340.5 &#x000b1; 151.9</th><th>0.278</th></tr></thead><tbody><tr><td><bold>HU 2 (Mid)</bold></td><td>285.9 &#x000b1; 138.9</td><td>349.0 &#x000b1; 147.3</td><td>342.4 &#x000b1; 146.8</td><td align="char">0.452</td></tr><tr><td><bold>HU 3 (Bottom)</bold></td><td>316.1 &#x000b1; 126.0</td><td>349.2 &#x000b1; 142.2</td><td>345.8 &#x000b1; 140.2</td><td align="char">0.658</td></tr><tr><td><bold>HU (Mean)</bold></td><td>291.7 &#x000b1; 137.9</td><td>348.8 &#x000b1; 145.0</td><td>342.9 &#x000b1; 144.5</td><td align="char">0.483</td></tr><tr><td><bold>Gradient I</bold><break/><bold>(HU 3</bold>&#x02013;<bold>1)</bold></td><td>50.6 &#x000b1; 26.7</td><td>34.9 &#x000b1; 28.6</td><td>36.5 &#x000b1; 28.6</td><td align="char">0.087</td></tr><tr><td><bold>Gradient II</bold><break/><bold>(HU 1</bold>&#x02013;<bold>2)</bold></td><td>26.4 &#x000b1; 10.1</td><td>30.6 &#x000b1; 26.9</td><td>30.2 &#x000b1; 25.7</td><td align="char">0.689</td></tr><tr><td><bold>Gradient III (HU 2</bold>&#x02013;<bold>3)</bold></td><td>37.3 &#x000b1; 34.7</td><td>24.9 &#x000b1; 21.4</td><td>26.2 &#x000b1; 23.2</td><td align="char">0.442</td></tr></tbody></table></table-wrap></p><p id="p0120">The ratio of the CT-density (HU) in the LAA/aorta was not different between stroke and non-stroke patients (&#x02212;91.8HU vs. 83.7HU; p&#x000a0;=&#x000a0;0.190), and the accuracy for both early and late phases was moderate (c&#x000a0;=&#x000a0;0.531, 95&#x000a0;% CI: 0.314&#x02013;748, p&#x000a0;=&#x000a0;0.736 for early phase) and poor (c&#x000a0;=&#x000a0;0.402, 95&#x000a0;% CI: 0.192&#x02013;613, p&#x000a0;=&#x000a0;0.367 for late phase), respectively.</p><sec id="s0060"><label>3.1</label><title>Left atrial wall thickness (LAWT) and periatrial fat attenuation index (FAI)</title><p id="p0125">Left atrial wall thickness (LAWT) and the periatrial fat attenuation index (FAI) were not different between stroke and non-stroke patients (LAWT: mean 3.2&#x000a0;mm&#x000a0;&#x000b1;&#x000a0;0.83 vs 3.5&#x000a0;&#x000b1;&#x000a0;0.69, p&#x000a0;=&#x000a0;0.117 and periatrial FAI: mean &#x02212;83.7&#x000a0;&#x000b1;&#x000a0;20.67 vs &#x02212;91&#x000a0;&#x000b1;&#x000a0;19.7, p&#x000a0;=&#x000a0;0.175, respectively).</p></sec><sec id="s0065"><label>3.2</label><title>Clinical and cardiovascular risk factors (CVRF) compared to LAA FD patterns by CTA</title><p id="p0130">On multivariate analysis, FD during late phase (p&#x000a0;=&#x000a0;0.059) (OR 5.66: 95&#x000a0;%CI: 0.936&#x02013;34.28) but not during early-phase were borderline associated with stroke, but none of the conventional major risk factors (<xref rid="t0030" ref-type="table">Table 5</xref>).&#x000a0;Univariate testing revealed only age (OR 1.3: 95&#x000a0;%CI: 1.041&#x02013;1.610) being associated with stroke but not CHA2DS2-Vasc-Score.&#x000a0;<xref rid="f0020" ref-type="fig">Fig. 4</xref>&#x000a0;shows a 76-year-old male patient with atrial fibrillation and a FD in the LAA with 52 HU, representing a thrombus.<table-wrap position="float" id="t0030"><label>Table 5</label><caption><p>Binary logistic regression analysis: Association of the major cardiovascular risk factors (CVRF) with stroke, and filling defects (FD) during late phase: only LAA filling defects (FD) during late phase showed a borderline association (p&#x000a0;=&#x000a0;0.059) with a high OR of 5.66.</p></caption><table frame="hsides" rules="groups"><thead><tr><th><bold>CVRF</bold></th><th><bold>OR</bold></th><th><bold>95&#x000a0;% CI</bold></th><th><bold>p-value</bold></th></tr></thead><tbody><tr><td>smoking</td><td align="char">0.471</td><td>0.044&#x02013;4.995</td><td align="char">0.532</td></tr><tr><td>arterial hypertension</td><td align="char">3.695</td><td>0.473&#x02013;28.873</td><td align="char">0.213</td></tr><tr><td>dyslipidemia</td><td align="char">0.419</td><td>0.071&#x02013;2.474</td><td align="char">0.337</td></tr><tr><td>diabetes</td><td align="char">0.000</td><td>0&#x02013;0</td><td align="char">0.998</td></tr><tr><td>obesity</td><td align="char">0.521</td><td>0.040&#x02013;6.812</td><td align="char">0.619</td></tr><tr><td>FD late phase</td><td align="char">5.666</td><td>0.936&#x02013;34.280</td><td align="char">0.059</td></tr><tr><td>positive familiy history</td><td align="char">0.821</td><td>0.138&#x02013;4.880</td><td align="char">0.828</td></tr></tbody></table></table-wrap><fig id="f0020"><label>Fig. 4</label><caption><p>Case example of a LAA FD during early phase with 52 HU, representing a thrombus in a 76&#x000a0;years old male patient with atrial fibrillation.Left: MPR, and right: Thin slice volume rendering technique (VRT).</p></caption><graphic xlink:href="gr4" id="lk00020"/></fig></p></sec></sec><sec id="s0070"><label>4</label><title>Discussion</title><p id="p0135">Our primary study findings are as follows: Cerebrovascular events can be predicted using pre-interventional identifiable LAA-FDs patterns on CTA in patients undergoing TAVI planning, particularly if the patterns continue into the late phase. The rates of stroke/TIA after&#x000a0;TAVI and persistent LAA-FD during late phase were significantly correlated in our study. Early-phase FD, on the other hand, did not exhibit a similarly robust association. Therefore, the late-phase FDs may be more accurate and significant indicators of stroke risk than transitory stasis artifacts since they more likely show the existence of thrombi rather than mere artifacts from lack of contrast agent mixing with blood during early phase. Importantly, out of 124 patients with severe aortic stenosis, 66.1&#x000a0;% underwent TAVI, 18.6&#x000a0;% underwent surgical treatment, and 15.3&#x000a0;% received conservative treatment &#x02013; so our cohort is a mixed and heterogenous cohort.</p><p id="p0140">So far, only one single-centric study has examined LAA-FD patterns for the prediction of stroke following TAVI. According to Okuno et al. <xref rid="b0115" ref-type="bibr">[23]</xref>, patients with LAA-FDs had higher rates of stroke after TAVI (9.2&#x000a0;%) (P &#x0003c; 0.001) and a higher history of cerebrovascular events (16.4&#x000a0;% vs. 10.9&#x000a0;%, P = 0.045) <xref rid="b0115" ref-type="bibr">[23]</xref>. Patients with a definite thrombus had the highest risk of disabling stroke (24.0&#x000a0;%), followed by a &#x0201c;HU-run-off&#x0201d; (8.0&#x000a0;%) in the LAA, a pattern that was similar to the HU-gradient we observed in our study. However, the authors evaluated only early and not late phase CT scans <xref rid="b0115" ref-type="bibr">[23]</xref>.</p><p id="p0145">Increased stroke risk is associated with the presence of thrombus or blood stagnation in the left atrial appendage (LAA) <xref rid="b0120" ref-type="bibr">[24]</xref> and LAA-FDs on CTA represent imaging markers for this condition. However, LAA-FDs during the early phase are less specific because they rather often reflect a lack of contrast agent filling during the early phase due to flow stasis due to the supine position of the patient. However, early phase FD may contain thrombi or sludge, which resolve later because the complete mixing of iodine contrast agent with blood in the systemic circulation takes several minutes. Therefore, during late CT phase, an artifact due to stasis is resolved, while a thrombus continues to appear hypodense with low CT attenuation values <xref rid="b0125" ref-type="bibr">[25]</xref>, <xref rid="b0130" ref-type="bibr">[26]</xref>. Definite left atrial appendage thrombi have been reported as predictors of stroke after TAVI by van Wiechen et al. <xref rid="b0055" ref-type="bibr">[11]</xref>. Another study by Szekely et al. <xref rid="b0060" ref-type="bibr">[12]</xref> found no difference in the short-term (in-hospital) cardiovascular event rate but observed an influence of LAA thrombi on mortality, a potential late complication of stroke occurring during long-term follow-up.</p><p id="p0150">Further, we performed a quantitative HU analysis of LAA-FD from tip to the base, revealing that an LAA HU gradient greater than 10 HU is another predictor of stroke in patients scheduled for TAVI, with high sensitivity (91&#x000a0;%) and moderate specificity (68&#x000a0;%) even during the early phase. During the late phase, the HU gradient's predictive power was improved. The non-stroke group exhibited a trend toward higher values in the LAA HU gradient between the tip and base, possibly pointing at a higher probability of mere artificial filling defects due to flow artifacts, rather than the presence of SEC or LAA thrombi. According to a ROC analysis, there was moderate discrimination capacity in the early phase (C = 0.592), but this improved in the late phase.</p><p id="p0155">Third, we describe another novel CT imaging biomarker, the LAA HU progression from early to late phase. This parameter has not been documented in the literature so far. Patients with stroke had a higher rate of FDs with HU progression from early to late phase (&#x0003e;10 HU). This imaging biomarker may improve the accuracy of stroke risk prediction following TAVI.</p><p id="p0160">Forth, the &#x0201c;ratio HU LAA/aorta&#x0201d; has been previously reported as a useful criterion to rule out LAA thrombi. In our cohort, the stroke group showed a tendency towards a lower ratio throughout both the early and late CT phases, however this trend did not reach a statistical significance in our cohort. Patel et al. previously described a cut-off of 0.75 as a criterion for differentiating artificial filling defects to exclude thrombi <xref rid="b0135" ref-type="bibr">[27]</xref>. Overall, the accuracy of CT for exclusion of thrombi is high <xref rid="b0130" ref-type="bibr">[26]</xref> if the LAA is completely filled with contrast <xref rid="b0080" ref-type="bibr">[16]</xref>. However,FDs in the LAA, especially during the early phase, are causing a high rate of false positive findings <xref rid="b0130" ref-type="bibr">[26]</xref> because they can represent either thrombi, sludge, or artificial filling detected due to stasis that usually resolve during the late phase. Adding a late phase improves the accuracy of CT. <xref rid="b0125" ref-type="bibr">[25]</xref>.</p><p id="p0165">Compared to early-phase FDs (139.42 HU), persistent filling defects had a considerably greater density of 233.19 HU. Furthermore, cerebrovascular events following TAVI were predicted by early-phase FD with a lower HU of &#x0003c;245 HU. Potential causes may include a comparatively high sludge content (&#x0201c;spontenaous echo contrast, SEC&#x0201d; on echocardiography) <xref rid="b0065" ref-type="bibr">[13]</xref> compared with thrombi that are consistently less dense in both the early and late phases (without increased density). Additionally, a longer circulation time following contrast agent injection and the presence of an artificial FD during the early phase may contribute to an increased filling of the LAA with iodinated contrast medium in the late phase. As it can be difficult to distinguish between the two, we measured the HU in the LAA at three separate locations (the tip, midsection, and bottom) and computed three distinct gradients, of which of which the gradient I (HU difference between the tip and the bottom of the LAA) had the highest diagnostic accuracy for the prediction of stroke.</p><p id="p0170">Our findings showed that traditional clinical risk factors such as hypertension, diabetes, and prior stroke did not significantly predict stroke incidence in our cohort. Stroke patients were older, and severe coronary artery disease (CAD) was more prevalent among stroke patients. However, multivariate analysis indicated that only late-phase LAA-FDs had a more pronounced association (OR 5.66) with stroke risk than these conventional factors and CHA2DS2-VASc-score. Therefore, using quantitative LAA-FD analysis may improve the accuracy of stroke prediction over the existing clinical risk assessments that rely on traditional risk variables such as the clinical risk score described by Thourani et al. (2019), which had moderate accuracy <xref rid="b0050" ref-type="bibr">[10]</xref>. However, more specific combined model ROC analysis are required, to test whether LAA-FD add incremental value to existing risk scores.</p><p id="p0175">Further, left atrial wall thickness (LAWT) did not significantly differ between the stroke patients and the control group. Other studies have reported LAWT as a predictor of stroke <xref rid="b0140" ref-type="bibr">[28]</xref>. However, patients with more severe left atrial remodeling as compared to our cohort were included in prior studies <xref rid="b0140" ref-type="bibr">[28]</xref>. LAWT was only mild (mean 3&#x000a0;mm) in our patients, which may explain why LAWT was not a prognosticator. As well, the <italic>peri</italic>-LAA fat attenuation index (FAI) showed no significant difference between the stroke/TIA and control group. Epicardial adipose tissue (EAT) volume may predict stroke, as reported in a <italic>meta</italic>-analysis pooling eight studies <xref rid="b0145" ref-type="bibr">[29]</xref>. This discrepancy may be explained by the low sample size in our study and by the distinct measurement technique applied in our cohort. We calculated only the periatrial FAI but not the entire epicardial fat volume.</p><p id="p0180">Finally, of note, despite the conventional clinical risk score for cerebrovascular events (CHA2DS2-VASc) was with 4.05 rather high in our cohort, it was overall not predictive for stroke. This result highlights the potential of CT-based imaging biomarkers to improve the precision of stroke and TIA event prediction <xref rid="b0110" ref-type="bibr">[22]</xref> following TAVI. Further, the composite cerebrovascular event rate consisting of both stroke and TIAs was rather high in our cohort compared to existing literature. This can be attributed to the very high-risk profile of our cohort, which include advanced age, elevated surgical and cardiovascular risk, and a high incidence of atrial fibrillation. Beyond, the inclusion of TIAs, which accounted for 25&#x000a0;% of all events contributed to the total high event rate.</p><p id="p0185">Of note, nowadays, also patients with intermediate surgical risk are recommended for TAVI according to novel guidelines. Therefore, our very high risk cohort is not representative for intermediate risk patients who are nowadays selected for TAVI.</p><p id="p0190">Limitations. Although the sample size of our study population is rather small, it is sufficiently powered, with an overall stroke rate of 9.6&#x000a0;%. Stroke rate was high due to the cohort profile (only very high risk patients were included). Second, interobserver variability was not calculated. Third, stroke events occurred both during short and long-term follow up (&#x0003e; 30&#x000a0;days), with the majority (75&#x000a0;%) after 30&#x000a0;days. Stroke mechanism may vary, and rather procedure related during short-term follow-up. Further, changes in medication during the follow-up period may affect stroke risk, but were not recorded. Furthermore, a bias could have been introduced because the impact of various antithrombotic medication regimens on stroke was not investigated. Different antithrombotic medication regimens are influencing outcomes after TAVI <xref rid="b0060" ref-type="bibr">[12]</xref>, other surgical procedures and conservative treatment.</p></sec><sec id="s0075"><label>5</label><title>Conclusion</title><p id="p0195">Our study demonstrates that persistent LAA-FDs during the late phase of CTA and early-phase FDs with low HU values are promising predictors of stroke in patients with severe aortic stenosis scheduled for surgical interventions. Identifying patients at risk for cerebrovascular events is a major challenge, and quantitative LAA-FD parameters could be useful to sharpen risk prediction. Future research to validate these findings in larger, external, or preferably multicentric cohorts would be desirable. In particular, the incremental value of LAA-FD patterns over conventional clinical risk scores for prediction of cerebrovascular events requires further investigations.</p></sec><sec id="s0080"><title>CRediT authorship contribution statement</title><p id="p0200"><bold>Pietro G. Lacaita:</bold> Writing &#x02013; reviewing &#x00026; editing, Data curation. <bold>Sven Bleckwenn:</bold> Writing &#x02013; review &#x00026; editing, Data curation. <bold>Fabian Barbieri:</bold> Writing &#x02013; review &#x00026; editing, Validation, Investigation. <bold>Yannick Scharll:</bold> Writing &#x02013; review &#x00026; editing, Data curation. <bold>Johannes Deeg:</bold> Writing &#x02013; review &#x00026; editing, Data curation. <bold>Nikolaos Bonaros:</bold> Writing &#x02013; review &#x00026; editing, Data curation. <bold>Gerlig Widmann:</bold> Writing &#x02013; review &#x00026; editing, Resources. <bold>Gudrun M. Feuchtner:</bold> Writing &#x02013; review &#x00026; editing, Writing &#x02013; original draft, Methodology, Data curation.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0205">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Muscente</surname><given-names>F.</given-names></name><name><surname>De Caterina</surname><given-names>R.</given-names></name></person-group><article-title>Risk of stroke after transcatheter aortic valve implant: the role of the new oral anticoagulants</article-title><source>Eur Heart J Suppl.</source><volume>21</volume><issue>Suppl B</issue><year>2019 Mar</year><fpage>B50</fpage><lpage>B51</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/suz01</pub-id><pub-id pub-id-type="pmid">30948946</pub-id>
</element-citation></ref><ref id="b0010"><label>2</label><mixed-citation publication-type="other" id="h0010">Sugiura K, Kohno T, Hayashida K, Fujisawa D, Kitakata H, Nakano N, Saito T, Hase H, Yoshijima N, Tsuruta H, Itabashi Y, Kohsaka S, Fukuda K. Elderly aortic stenosis patients' perspectives on treatment goals in transcatheter aortic valvular replacement. ESC Heart Fail. 2022 Aug;9(4):2695-2702. doi: 10.1002/ehf2.14008. Epub 2022 Jun 8. PMID: 35674410; PMCID: PMC9288810.</mixed-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Grabert</surname><given-names>S.</given-names></name><name><surname>Lange</surname><given-names>R.</given-names></name><name><surname>Bleiziffer</surname><given-names>S.</given-names></name></person-group><article-title>Incidence and causes of silent and symptomatic stroke following surgical and transcatheter aortic valve replacement: a comprehensive review</article-title><source>Interact Cardiovasc Thorac Surg</source><volume>23</volume><year>2016</year><fpage>469</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">27241049</pub-id>
</element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Huded</surname><given-names>C.P.</given-names></name><name><surname>Tuzcu</surname><given-names>E.M.</given-names></name><name><surname>Krishnaswamy</surname><given-names>A.</given-names></name><name><surname>Mick</surname><given-names>S.L.</given-names></name><name><surname>Kleiman</surname><given-names>N.S.</given-names></name><name><surname>Svensson</surname><given-names>L.G.</given-names></name><name><surname>Carroll</surname><given-names>J.</given-names></name><name><surname>Thourani</surname><given-names>V.H.</given-names></name><name><surname>Kirtane</surname><given-names>A.J.</given-names></name><name><surname>Manandhar</surname><given-names>P.</given-names></name><name><surname>Kosinski</surname><given-names>A.S.</given-names></name><name><surname>Vemulapalli</surname><given-names>S.</given-names></name><name><surname>Kapadia</surname><given-names>S.R.</given-names></name></person-group><article-title>Association Between Transcatheter Aortic Valve Replacement and Early Postprocedural Stroke</article-title><source>JAMA.</source><volume>321</volume><issue>23</issue><year>2019 Jun 18</year><fpage>2306</fpage><lpage>2315</lpage><pub-id pub-id-type="pmid">31211345</pub-id>
</element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>J.D.</given-names></name><name><surname>Mack</surname><given-names>M.J.</given-names></name><name><surname>Vemulapalli</surname><given-names>S.</given-names></name><name><surname>Herrmann</surname><given-names>H.C.</given-names></name><name><surname>Gleason</surname><given-names>T.G.</given-names></name><name><surname>Hanzel</surname><given-names>G.</given-names></name><name><surname>Deeb</surname><given-names>G.M.</given-names></name><name><surname>Thourani</surname><given-names>V.H.</given-names></name><name><surname>Cohen</surname><given-names>D.J.</given-names></name><name><surname>Desai</surname><given-names>N.</given-names></name><name><surname>Kirtane</surname><given-names>A.J.</given-names></name><name><surname>Fitzgerald</surname><given-names>S.</given-names></name><name><surname>Michaels</surname><given-names>J.</given-names></name><name><surname>Krohn</surname><given-names>C.</given-names></name><name><surname>Masoudi</surname><given-names>F.A.</given-names></name><name><surname>Brindis</surname><given-names>R.G.</given-names></name><name><surname>Bavaria</surname><given-names>J.E.</given-names></name></person-group><article-title>STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement</article-title><source>J Am Coll Cardiol.</source><volume>76</volume><issue>21</issue><year>2020 Nov 24</year><fpage>2492</fpage><lpage>2516</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2020.09.595</pub-id><comment>PMID: 33213729</comment><pub-id pub-id-type="pmid">33213729</pub-id>
</element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Castelo</surname><given-names>A.</given-names></name><name><surname>Grazina</surname><given-names>A.</given-names></name><name><surname>Teixeira</surname><given-names>B.</given-names></name><name><surname>Mendon&#x000e7;a</surname><given-names>T.</given-names></name><name><surname>Rodrigues</surname><given-names>I.</given-names></name><name><surname>Garcia Br&#x000e1;s</surname><given-names>P.</given-names></name><name><surname>Vaz Ferreira</surname><given-names>V.</given-names></name><name><surname>Ramos</surname><given-names>R.</given-names></name><name><surname>Fiarresga</surname><given-names>A.</given-names></name><name><surname>Cacela</surname><given-names>D.</given-names></name><name><surname>Cruz</surname><given-names>F.R.</given-names></name></person-group><article-title>Outcomes and predictors of periprocedural stroke after transcatheter aortic valve implantation</article-title><source>J Stroke Cerebrovasc Dis.</source><volume>32</volume><issue>5</issue><year>2023 May</year><object-id pub-id-type="publisher-id">107054</object-id><pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2023.107054</pub-id><comment>Epub 2023 Mar 5. PMID: 36881984</comment></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Hynes</surname><given-names>B.G.</given-names></name><name><surname>Rodes-Cabau</surname><given-names>J.</given-names></name></person-group><article-title>Transcatheter aortic valve implantation and cerebrovascular events: the current state of the art</article-title><source>Ann N Y Acad Sci.</source><volume>1254</volume><year>2012</year><fpage>151</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">22548581</pub-id>
</element-citation></ref><ref id="b0040"><label>8</label><mixed-citation publication-type="other" id="h0040">Butala NM, Kapadia SR, Secemsky EA, Gallup D, Kosinski AS, Vemulapalli S, Messenger JC, Yeh RW, Cohen DJ. Impact of Cerebral Embolic Protection Devices on Disabling Stroke after Transcatheter Aortic Valve Replacement: Updated Results from the STS/ACC TVT Registry. Circ Cardiovasc Interv. 2024 Jun 5. doi: 10.1161/CIRCINTERVENTIONS.123.013697. Epub ahead of print. PMID: 38837174.</mixed-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Jimenez Diaz</surname><given-names>V.A.</given-names></name><name><surname>Estevez Loureiro</surname><given-names>R.</given-names></name><name><surname>Baz Alonso</surname><given-names>J.A.</given-names></name><name><surname>Juan Salvadores</surname><given-names>P.</given-names></name><name><surname>Bastos Fernandez</surname><given-names>G.</given-names></name><name><surname>Caneiro Queija</surname><given-names>B.</given-names></name><name><surname>Veiga Garcia</surname><given-names>C.</given-names></name><name><surname>I&#x000f1;iguez</surname><given-names>R.A.</given-names></name></person-group><article-title>Stroke prevention during and after transcatheter aortic valve implantation: From cerebral protection devices to antithrombotic management</article-title><source>Front Cardiovasc Med.</source><volume>17</volume><issue>9</issue><year>2022 Oct</year><object-id pub-id-type="publisher-id">958732</object-id><pub-id pub-id-type="other">10.3389/fcvm.2022.958732. PMID: 36324741; PMCID: PMC9618870</pub-id></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Thourani</surname><given-names>V.H.</given-names></name><name><surname>O'Brien</surname><given-names>S.M.</given-names></name><name><surname>Kelly</surname><given-names>J.J.</given-names></name><name><surname>Cohen</surname><given-names>D.J.</given-names></name><name><surname>Peterson</surname><given-names>E.D.</given-names></name><name><surname>Mack</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Development and Application of a Risk Prediction Model for In-Hospital Stroke After Transcatheter Aortic Valve Replacement: A Report From The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry</article-title><source>Ann Thorac Surg.</source><volume>107</volume><issue>4</issue><year>2019</year><fpage>1097</fpage><lpage>1103</lpage><pub-id pub-id-type="pmid">30529671</pub-id>
</element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>van Wiechen</surname><given-names>M.P.</given-names></name><name><surname>Faure</surname><given-names>M.E.</given-names></name><name><surname>Hokken</surname><given-names>T.W.</given-names></name><name><surname>Ooms</surname><given-names>J.F.</given-names></name><name><surname>de Ronde-Tillmans</surname><given-names>M.J.</given-names></name><name><surname>Hirsch</surname><given-names>A.</given-names></name><name><surname>Daemen</surname><given-names>J.</given-names></name><name><surname>de Jaegere</surname><given-names>P.P.</given-names></name><name><surname>Budde</surname><given-names>R.P.J.</given-names></name><name><surname>Van Mieghem</surname><given-names>N.M.</given-names></name></person-group><article-title>Left atrial appendage thrombus and cerebrovascular events post-transcatheter aortic valve implantation</article-title><source>Eur Heart J Cardiovasc Imaging.</source><volume>23</volume><issue>10</issue><year>2022 Sep 10</year><fpage>1345</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1093/ehjci/jeab139</pub-id><comment>PMID: 34322706</comment><pub-id pub-id-type="pmid">34322706</pub-id>
</element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Szekely</surname><given-names>Y.</given-names></name><name><surname>Shmilovich</surname><given-names>H.</given-names></name><name><surname>Hochstadt</surname><given-names>A.</given-names></name><name><surname>Ghantous</surname><given-names>E.</given-names></name><name><surname>Topilsky</surname><given-names>Y.</given-names></name><name><surname>Aviram</surname><given-names>G.</given-names></name><name><surname>Hadad</surname><given-names>Y.</given-names></name><name><surname>Arbel</surname><given-names>Y.</given-names></name><name><surname>Konigstein</surname><given-names>M.</given-names></name><name><surname>Banai</surname><given-names>S.</given-names></name><name><surname>Finkelstein</surname><given-names>A.</given-names></name><name><surname>Halkin</surname><given-names>A.</given-names></name></person-group><article-title>Long-term implications of left atrial appendage thrombus identified incidentally by pre-procedural cardiac computed tomography angiography in patients undergoing transcatheter aortic valve replacement</article-title><source>Eur Heart J Cardiovasc Imaging.</source><volume>22</volume><issue>5</issue><year>2021 Apr 28</year><fpage>563</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1093/ehjci/jeaa030</pub-id><comment>PMID: 32154881</comment><pub-id pub-id-type="pmid">32154881</pub-id>
</element-citation></ref><ref id="b0065"><label>13</label><mixed-citation publication-type="other" id="h0065">Siddiqui MA, Holmberg MJ, Khan IA. Spontaneous echo contrast in left atrial appendage during sinus rhythm. Tex Heart Inst J. 2001;28(4):322-3. PMID: 11777163; PMCID: PMC101214.</mixed-citation></ref><ref id="b0070"><label>14</label><mixed-citation publication-type="other" id="h0070">an der Maten G, Meijs MFL, Timmer JR, Brouwers PJAM, von Birgelen C, Coutinho JM, Bouma BJ, Kerkhoff H, Helming AM, van Tuijl JH, van der Meer NA, Saxena R, Ebink C, van der Palen J, den Hertog HM. Routine transthoracic echocardiography in ischaemic stroke or transient ischaemic attack of undetermined cause: a prospective multicentre study. Neth Heart J. 2024 Feb;32(2):91-98. doi: 10.1007/s12471-023-01819-7. Epub 2023 Oct 23. PMID: 37870709; PMCID: PMC10834921.</mixed-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>Ouchi</surname><given-names>K.</given-names></name><name><surname>Sakuma</surname><given-names>T.</given-names></name><name><surname>Higuchi</surname><given-names>T.</given-names></name><name><surname>Yoshida</surname><given-names>J.</given-names></name><name><surname>Narui</surname><given-names>R.</given-names></name><name><surname>Nojiri</surname><given-names>A.</given-names></name><name><surname>Yamane</surname><given-names>T.</given-names></name><name><surname>Ojiri</surname><given-names>H.</given-names></name></person-group><article-title>Filling defects in the left atrial appendage restricted to the early phase of cardiac computed tomography as a potential risk of left atrial appendage dysfunction</article-title><source>J Cardiol.</source><volume>79</volume><issue>2</issue><year>2022 Feb</year><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.jjcc.2021.09.011</pub-id><comment>Epub 2021 Oct 2 PMID: 34610891</comment><pub-id pub-id-type="pmid">34610891</pub-id>
</element-citation></ref><ref id="b0080"><label>16</label><mixed-citation publication-type="other" id="h0080">Romero J, Husain SA, Kelesidis I, Sanz J, Medina HM, Garcia MJ. Detection of left atrial appendage thrombus by cardiac computed tomography in patients with atrial fibrillation: a meta-analysis. Circ Cardiovasc Imaging. 2013 Mar 1;6(2):185-94. doi: 10.1161/CIRCIMAGING.112.000153. Epub 2013 Feb 13. PMID: 23406625.FD.</mixed-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Blanke</surname><given-names>P.</given-names></name><name><surname>Weir-McCall</surname><given-names>J.R.</given-names></name><name><surname>Achenbach</surname><given-names>S.</given-names></name><name><surname>Delgado</surname><given-names>V.</given-names></name><name><surname>Hausleiter</surname><given-names>J.</given-names></name><name><surname>Jilaihawi</surname><given-names>H.</given-names></name><name><surname>Marwan</surname><given-names>M.</given-names></name><name><surname>Norgaard</surname><given-names>B.L.</given-names></name><name><surname>Piazza</surname><given-names>N.</given-names></name><name><surname>Schoenhagen</surname><given-names>P.</given-names></name><name><surname>Leipsic</surname><given-names>J.A.</given-names></name></person-group><article-title>Computed tomography imaging in the context of transcatheter aortic valve implantation (TAVI) / transcatheter aortic valve replacement (TAVR): An expert consensus document of the Society of Cardiovascular Computed Tomography</article-title><source>J Cardiovasc Comput Tomogr.</source><year>2019</year></element-citation></ref><ref id="b0090"><label>18</label><mixed-citation publication-type="other" id="h0090">Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Mu&#x000f1;oz D, Rosenhek R, Sj&#x000f6;gren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017 Sep 21;38(36):2739-2791. doi: 10.1093/eurheartj/ehx391. PMID: 28886619.</mixed-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B.</given-names></name><name><surname>Mancia</surname><given-names>G.</given-names></name><name><surname>Spiering</surname><given-names>W.</given-names></name><etal/></person-group><article-title>2018 ESC/ESH Guidelines for the management of arterial hypertension</article-title><source>Eur Heart J</source><volume>39</volume><issue>33</issue><year>2018</year><fpage>3021</fpage><lpage>3104</lpage><pub-id pub-id-type="pmid">30165516</pub-id>
</element-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Mach</surname><given-names>F.</given-names></name><name><surname>Baigent</surname><given-names>C.</given-names></name><name><surname>Catapano</surname><given-names>A.L.</given-names></name><etal/></person-group><article-title>2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk</article-title><source>Atherosclerosis</source><volume>290</volume><issue>1</issue><year>2019</year><fpage>140</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">31591002</pub-id>
</element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Cosentino</surname><given-names>F.</given-names></name><name><surname>Grant</surname><given-names>P.J.</given-names></name><name><surname>Aboyans</surname><given-names>V.</given-names></name><etal/></person-group><article-title>2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD</article-title><source>Eur Heart J</source><volume>41</volume><issue>2</issue><year>2020</year><fpage>255</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">31497854</pub-id>
</element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Lansky</surname><given-names>A.J.</given-names></name><name><surname>Mess&#x000e9;</surname><given-names>S.R.</given-names></name><name><surname>Brickman</surname><given-names>A.M.</given-names></name><name><surname>Dwyer</surname><given-names>M.</given-names></name><name><surname>van der Worp</surname><given-names>H.B.</given-names></name><name><surname>Lazar</surname><given-names>R.M.</given-names></name><name><surname>Pietras</surname><given-names>C.G.</given-names></name><name><surname>Abrams</surname><given-names>K.J.</given-names></name><name><surname>McFadden</surname><given-names>E.</given-names></name><name><surname>Petersen</surname><given-names>N.H.</given-names></name><name><surname>Browndyke</surname><given-names>J.</given-names></name><name><surname>Prendergast</surname><given-names>B.</given-names></name><name><surname>Ng</surname><given-names>V.G.</given-names></name><name><surname>Cutlip</surname><given-names>D.E.</given-names></name><name><surname>Kapadia</surname><given-names>S.</given-names></name><name><surname>Krucoff</surname><given-names>M.W.</given-names></name><name><surname>Linke</surname><given-names>A.</given-names></name><name><surname>Moy</surname><given-names>C.S.</given-names></name><name><surname>Schofer</surname><given-names>J.</given-names></name><name><surname>van Es</surname><given-names>G.A.</given-names></name><name><surname>Virmani</surname><given-names>R.</given-names></name><name><surname>Popma</surname><given-names>J.</given-names></name><name><surname>Parides</surname><given-names>M.K.</given-names></name><name><surname>Kodali</surname><given-names>S.</given-names></name><name><surname>Bilello</surname><given-names>M.</given-names></name><name><surname>Zivadinov</surname><given-names>R.</given-names></name><name><surname>Akar</surname><given-names>J.</given-names></name><name><surname>Furie</surname><given-names>K.L.</given-names></name><name><surname>Gress</surname><given-names>D.</given-names></name><name><surname>Voros</surname><given-names>S.</given-names></name><name><surname>Moses</surname><given-names>J.</given-names></name><name><surname>Greer</surname><given-names>D.</given-names></name><name><surname>Forrest</surname><given-names>J.K.</given-names></name><name><surname>Holmes</surname><given-names>D.</given-names></name><name><surname>Kappetein</surname><given-names>A.P.</given-names></name><name><surname>Mack</surname><given-names>M.</given-names></name><name><surname>Baumbach</surname><given-names>A.</given-names></name></person-group><article-title>Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative</article-title><source>J Am Coll Cardiol.</source><volume>69</volume><issue>6</issue><year>2017 Feb 14</year><fpage>679</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2016.11.045</pub-id><comment>PMID: 2818351</comment><pub-id pub-id-type="pmid">28183511</pub-id>
</element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Okuno</surname><given-names>T.</given-names></name><name><surname>Lanz</surname><given-names>J.</given-names></name><name><surname>Stortecky</surname><given-names>S.</given-names></name><name><surname>Heg</surname><given-names>D.</given-names></name><name><surname>Bernhard</surname><given-names>B.</given-names></name><name><surname>Gr&#x000e4;ni</surname><given-names>C.</given-names></name><name><surname>Huber</surname><given-names>A.</given-names></name><name><surname>Praz</surname><given-names>F.</given-names></name><name><surname>R&#x000e4;ber</surname><given-names>L.</given-names></name><name><surname>Valgimigli</surname><given-names>M.</given-names></name><name><surname>Siontis</surname><given-names>G.C.M.</given-names></name><name><surname>Windecker</surname><given-names>S.</given-names></name><name><surname>Pilgrim</surname><given-names>T.</given-names></name></person-group><article-title>Clinical impact of left atrial appendage filling defects in patients undergoing transcatheter aortic valve implantation</article-title><source>Eur Heart J Cardiovasc Imaging.</source><volume>23</volume><issue>10</issue><year>2022 Sep 10</year><fpage>1354</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1093/ehjci/jeab142</pub-id><comment>PMID: 34463717</comment><pub-id pub-id-type="pmid">34463717</pub-id>
</element-citation></ref><ref id="b0120"><label>24</label><mixed-citation publication-type="other" id="h0120">Di Minno MN, Ambrosino P, Dello Russo A, Casella M, Tremoli E, Tondo C. Prevalence of left atrial thrombus in patients with non-valvular atrial fibrillation. A systematic review and meta-analysis of the literature. Thromb Haemost. 2016 Mar;115(3):663-77. doi: 10.1160/TH15-07-0532. Epub 2015 Nov 26. PMID: 26607276.</mixed-citation></ref><ref id="b0125"><label>25</label><mixed-citation publication-type="other" id="h0125">Spagnolo P, Giglio M, Di Marco D, Canna&#x000f2; PM, Agricola E, Della Bella PE, Monti CB, Sardanelli F. Diagnosis of left atrial appendage thrombus in patients with atrial fibrillation: delayed contrast-enhanced cardiac CT. Eur Radiol. 2021 Mar;31(3):1236-1244. doi: 10.1007/s00330-020-07172-2. Epub 2020 Sep 4. PMID: 32886202; PMCID: PMC7880950.</mixed-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>M.D.</given-names></name><name><surname>Neilan</surname><given-names>T.G.</given-names></name><name><surname>Jassal</surname><given-names>D.S.</given-names></name><name><surname>Samy</surname><given-names>B.</given-names></name><name><surname>Nasir</surname><given-names>K.</given-names></name><name><surname>Hoffmann</surname><given-names>U.</given-names></name><name><surname>Sarwar</surname><given-names>A.</given-names></name><name><surname>Butler</surname><given-names>J.</given-names></name><name><surname>Brady</surname><given-names>T.J.</given-names></name><name><surname>Cury</surname><given-names>R.C.</given-names></name></person-group><article-title>Multidetector computed tomography for the detection of left atrial appendage thrombus: a comparative study with transesophageal echocardiography</article-title><source>J Comput Assist Tomogr</source><volume>31</volume><year>2007</year><fpage>905</fpage><lpage>909</lpage><pub-id pub-id-type="pmid">18043355</pub-id>
</element-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A.</given-names></name><name><surname>Au</surname><given-names>E.</given-names></name><name><surname>Donegan</surname><given-names>K.</given-names></name><name><surname>Kim</surname><given-names>R.J.</given-names></name><name><surname>Lin</surname><given-names>F.Y.</given-names></name><name><surname>Stein</surname><given-names>K.M.</given-names></name><etal/></person-group><article-title>Multidetector row computed tomography for identification of left atrial appendage filling defects in patients undergoing pulmonary vein isolation for treatment of atrial fibrillation: comparison with transesophageal echocardiography</article-title><source>Heart Rhythm.</source><volume>5</volume><issue>2</issue><year>2008</year><fpage>253</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">18242550</pub-id>
</element-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Adukauskaite</surname><given-names>A.</given-names></name><name><surname>Barbieri</surname><given-names>F.</given-names></name><name><surname>Senoner</surname><given-names>T.</given-names></name><name><surname>Plank</surname><given-names>F.</given-names></name><name><surname>Knoflach</surname><given-names>M.</given-names></name><name><surname>Boehme</surname><given-names>C.</given-names></name><name><surname>Hintringer</surname><given-names>F.</given-names></name><name><surname>Mueller</surname><given-names>S.</given-names></name><name><surname>Bauer</surname><given-names>A.</given-names></name><name><surname>Feuchtner</surname><given-names>G.</given-names></name><name><surname>Dichtl</surname><given-names>W.</given-names></name></person-group><article-title>Left Atrial Appendage Morphology and Left Atrial Wall Thickness Are Associated with Cardio-Embolic Stroke</article-title><source>J Clin Med.</source><volume>9</volume><issue>12</issue><year>2020 Dec 5</year><fpage>3944</fpage><pub-id pub-id-type="other">10.3390/jcm9123944. PMID: 33291376; PMCID: PMC7762068</pub-id><pub-id pub-id-type="pmid">33291376</pub-id>
</element-citation></ref><ref id="b0145"><label>29</label><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name><surname>Rosa</surname><given-names>M.I.</given-names></name><name><surname>Grande</surname><given-names>A.J.</given-names></name><name><surname>Lima</surname><given-names>L.D.</given-names></name><name><surname>Dondossola</surname><given-names>E.R.</given-names></name><name><surname>Uggioni</surname><given-names>M.L.R.</given-names></name><name><surname>Hernandez</surname><given-names>A.V.</given-names></name><name><surname>Tse</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Pontes-Neto</surname><given-names>O.M.</given-names></name><name><surname>Biondi-Zoccai</surname><given-names>G.</given-names></name><name><surname>Neto</surname><given-names>M.G.</given-names></name><name><surname>Dur&#x000e3;es</surname><given-names>A.R.</given-names></name><name><surname>S&#x000e1;</surname><given-names>M.P.B.O.</given-names></name><name><surname>Resende</surname><given-names>E.S.</given-names></name><name><surname>Roever</surname><given-names>L.</given-names></name></person-group><article-title>Association Between Epicardial Adipose Tissue and Stroke</article-title><source>Front Cardiovasc Med.</source><volume>21</volume><issue>8</issue><year>2021 Apr</year><object-id pub-id-type="publisher-id">658445</object-id><pub-id pub-id-type="other">10.3389/fcvm.2021.658445. PMID: 33969022; PMCID: PMC8096977</pub-id></element-citation></ref></ref-list><sec id="s0090" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0215">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="m0005"><caption><title>Supplementary Data 1</title></caption><media xlink:href="mmc1.docx"/></supplementary-material></p></sec><fn-group><fn id="s0085" fn-type="supplementary-material"><label>Appendix A</label><p id="p0210">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijcha.2024.101576" id="ir005">https://doi.org/10.1016/j.ijcha.2024.101576</ext-link>.</p></fn></fn-group></back></article>